Anaptysbio (ANAB) Change in Accured Expenses (2016 - 2026)

Anaptysbio (ANAB) has 11 years of Change in Accured Expenses data on file, last reported at -$17.8 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 25.86% year-over-year to -$17.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$81.1 million (down 53.92% YoY) and the FY2025 annual result came in at -$87.3 million, down 158.08% from the prior year.
• Change in Accured Expenses advanced to -$17.8 million in Q1 2026, from -$22.4 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $8.5 million in Q1 2023 to a low of -$40.0 million in Q4 2024.
• A 5-year average of -$7.0 million and a median of -$1.5 million in 2023 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses surged 8706.67% — and 2024, when it sank 2573.36%.
• Tracing ANAB's Change in Accured Expenses over 5 years: stood at $4.8 million in 2022, then slumped by 131.0% to -$1.5 million in 2023, then slumped by 2573.36% to -$40.0 million in 2024, then jumped by 44.04% to -$22.4 million in 2025, then rose by 20.49% to -$17.8 million in 2026.
• The last three Change in Accured Expenses figures came in at -$17.8 million (Q1 2026), -$22.4 million (Q4 2025), and -$18.6 million (Q3 2025), per Business Quant data.